{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071474","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.389299+00:00","generated_at":"2026-05-21T08:22:43.100236+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kodiak Sciences Q1 net loss $57.5M ($1.09/shr), cash $138.9M; pipeline on track for 2026 data","bullets":["Net loss $57.5M ($1.09/shr) vs $43.0M ($0.82) in Q1 2024; non-cash stock comp $15.9M.","Cash and cash equivalents $138.9M; company believes current cash funds operations into 2026.","R&D expenses $43.6M, up from $29.9M YoY, driven by increased clinical and manufacturing activities.","Phase 3 GLOW2 (DR), DAYBREAK (wet AMD) for tarcocimab and KSI-501; Phase 1b APEX data for KSI-101 expected.","Investor R&D Update scheduled for July 16, 2025; topline data targeted in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071474","json":"https://secwatch.observer/filing/0000950170-25-071474.json","markdown":"https://secwatch.observer/filing/0000950170-25-071474.md","text":"https://secwatch.observer/filing/0000950170-25-071474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017025071474/0000950170-25-071474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017025071474/kod-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:22:43.100236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}